Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group

P. M. Schlag
Department of Surgery, University of Heidelberg, Germany.

Of 77 patients with potentially resectable squamous cell carcinoma of the esophagus who were asked to participate in a phase III trial of treatment with either immediate surgery (n = 24) or surgery plus preoperative chemotherapy (n = 22), only 46 agreed to randomization. A priori, 13 patients chose chemotherapy before surgery and 18 patients chose surgery only. The complete chemotherapy program consisted of three cycles with fluorouracil, 1 g/m2 per day for 5 days, and cisplatin, 20 mg/m2 per day for 5 days. The response rate to chemotherapy was 50% (17 of 34 patients). Side effects of therapy were higher than expected based on results of previous phase II studies. Two drug-related deaths were observed. The resectability rate for patients in the surgery only group was 79% (33 of 42 patients) compared with 70% (19 of 27 patients) for patients receiving chemotherapy. The postoperative rates of septic complications (41% [11 of 27 patients] vs 26% [11 of 42 patients]) and respiratory disorders (48% [13 of 27 patients] vs 31% [13 of 42 patients]) were higher for patients with preoperative chemotherapy than for those treated with surgery only. Surgery-related mortality was increased in the chemotherapy group (19% [five of 27 patients]) compared with the surgery only group (10% [four of 42 patients]). Patients responding to preoperative chemotherapy had prolonged survival (median, 13 months) compared with nonresponders (median, 5 months), but the median survival for the chemotherapy group and the surgery only group was identical (10 months). We conclude that the preoperative chemotherapy regime used in this multi-institutional trial neither influences resectability nor increases the overall survival of patients with localized esophageal cancer. However, preoperative chemotherapy is associated with considerable side effects and a high postoperative mortality rate.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Better Survival in Patients with Esophageal Cancer After Surgical Treatment in University Hospitals: A Plea for Performance by Surgical Oncologists
Verhoef et al.
Ann. Surg. Oncol. 2007;14:1678-1687.
ABSTRACT | FULL TEXT  

Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment
DeMeester
Ann. Surg. Oncol. 2006;13:12-30.
ABSTRACT | FULL TEXT  

Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma
Lee et al.
Ann. Thorac. Surg. 2005;80:1170-1175.
ABSTRACT | FULL TEXT  

High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer
Moore Joshi et al.
Clin. Cancer Res. 2005;11:2215-2221.
ABSTRACT | FULL TEXT  

Proliferation Potential-Related Protein, an Ideal Esophageal Cancer Antigen for Immunotherapy, Identified Using Complementary DNA Microarray Analysis
Yoshitake et al.
Clin. Cancer Res. 2004;10:6437-6448.
ABSTRACT | FULL TEXT  

Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer: Experience at a Single Institution
Malaisrie et al.
Arch Surg 2004;139:532-539.
ABSTRACT | FULL TEXT  

Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches
Koshy et al.
The Oncologist 2004;9:147-159.
ABSTRACT | FULL TEXT  

The Clinical Efficacy of Neoadjuvant Chemotherapy in Squamous Esophageal Cancer: A Prospective Nonrandomized Study of Pulse and Continuous-Infusion Regimens With Cisplatin and 5-Fluorouracil
Chan et al.
Ann. Surg. Oncol. 2002;9:617-624.
ABSTRACT | FULL TEXT  

Multimodality therapy for resectable cancer of the thoracic esophagus
Entwistle and Goldberg
Ann. Thorac. Surg. 2002;73:1009-1015.
ABSTRACT | FULL TEXT  

Locoregional Cellular Immunotherapy for Patients with Advanced Esophageal Cancer
Toh et al.
Clin. Cancer Res. 2000;6:4663-4673.
ABSTRACT | FULL TEXT  

Does Paclitaxel Improve the Chemoradiotherapy of Locoregionally Advanced Esophageal Cancer? A Nonrandomized Comparison With Fluorouracil-Based Therapy
Adelstein et al.
JCO 2000;18:2032-2039.
ABSTRACT | FULL TEXT  

Surgical Management of Esophageal Carcinoma
Reed
The Oncologist 1999;4:95-105.
ABSTRACT | FULL TEXT  

PREOPERATIVE CHEMOTHERAPY VERSUS SURGICAL THERAPY ALONE FOR SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS: A PROSPECTIVE RANDOMIZED TRIAL
Law et al.
J. Thorac. Cardiovasc. Surg. 1997;114:210-217.
ABSTRACT | FULL TEXT  

Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus
Bosset et al.
NEJM 1997;337:161-167.
ABSTRACT | FULL TEXT